"How Much Time Do I Have?": Communicating Prognosis in the Era of Exceptional Responders

Thomas W LeBlanc1, Jennifer S Temel1, Paul R Helft1

  • 1From the Cancer Patient Experience Research Program, Duke Cancer Institute, Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC; Massachusetts General Hospital, Boston, MA; Department of Medicine, Division of Hematology/Oncology, Indiana University Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN.